A Multicenter, Randomized, Cross-Over, Open-label Study to Evaluate the Adherence, Preference, and Satisfaction of Denosumab and Alendronate [alendronic acid] in Postmenopausal Women With Low Bone Mineral Density.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Denosumab (Primary) ; Alendronic acid
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Acronyms DAPS
- Sponsors Amgen
- 26 Oct 2019 Results of post hoc analysis evaluating subjects randomized to denosumab published in the Journal of Clinical Endocrinology and Metabolism
- 01 Jan 2012 Final results published in Osteoporosis International.
- 23 Mar 2011 Results have been presented at ECCEO11-IOF according to an Amgen media release; results were also reported in the media release.